
HeartBeam (BEAT) Stock Forecast & Price Target
HeartBeam (BEAT) Analyst Ratings
Bulls say
HeartBeam Inc. is positioned to capitalize on a significant market opportunity, with the potential to expand its annual revenue to between $1.3 billion and $2.6 billion by targeting 2.6 million elevated-risk patients and catering to the growing demand for early remote cardiac diagnoses. The company's proprietary Vector Electrocardiography technology has demonstrated high sensitivity (92-100%) and improving specificity (54-58%) in clinical trials, which strengthens its prospects for FDA clearance and subsequent market adoption. Additionally, the global mobile ECG devices market is projected to grow from $4.1 billion in 2024 to $8.9 billion by 2032, supporting the increasing prevalence of cardiac diseases and the rising demand for innovative telehealth solutions.
Bears say
HeartBeam Inc faces significant challenges that could adversely affect its financial performance and stock outlook. The company's potential inability to obtain timely reimbursement for its products may result in limited market demand, leading to diminished revenue and operating results. Furthermore, the auditors' going-concern opinion raises substantial doubts about HeartBeam's long-term viability without new funding, compounding concerns about negative cash flows projected for 2025 and 2026, potential stock dilution, and the risk of operational delays or interruptions due to regulatory changes and compliance issues.
This aggregate rating is based on analysts' research of HeartBeam and is not a guaranteed prediction by Public.com or investment advice.
HeartBeam (BEAT) Analyst Forecast & Price Prediction
Start investing in HeartBeam (BEAT)
Order type
Buy in
Order amount
Est. shares
0 shares